Skip to Content

'
Mimi I. Hu, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director, Bone Healthcare Program, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Fellowship Program Director, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Clinical Assistant Professor, Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston, TX

Bio Statement

Dr. Mimi I. Hu graduated from Rice University with a degree in mechanical engineering. She obtained her medical degree from the University of Texas - Houston Health Sciences Center. She completed her residency and endocrine fellowship at the Baylor College of Medicine, where she also served as chief medical resident. After completion of her research fellowship at M. D. Anderson, she joined the faculty in 2007 as an assistant professor in the department of endocrine neoplasia and hormonal disorders. Dr. Hu's clinical expertise is in the evaluation and treatment of patients with thyroid carcinoma, hereditary endocrine neoplasia disorders and metabolic bone and mineral disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders.

Research Interests

Novel therapeutics for thyroid cancer
Medullary thyroid cancer
Bone and mineral metabolism disorders

Clinical Interests

Thyroid carcinoma - differentiated and medullary
Multiple endocrine neoplasia, Types 1 and 2
Bone and mineral metabolism disorders
Parathyroid disorders
Pituitary tumors
Endocrine effects of cancer and its therapies

For general clinic information, please visit the Department of Endocrine Neoplasia and Hormonal Disorders' contact information website listed below:

Contact Information

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 1461
Houston, TX 77030-4009
Room Number: FCT12.5022
Phone: 713-792-2841
Fax: 713-794-4065

Education & Training

Degree-Granting Education

2000 University of Texas Houston Health Science Center, Houston, TX, MD, Medicine
1993 Rice University, Houston, TX, BS, Mechanical Engineering

Postgraduate Training

8/2005-9/2008 Clinical Research Curriculum, Center for Clinical Research and Evidence-Based Medicine, University of Texas-Houston Medical School, Houston, TX, Kathleen Kennedy, MD
7/2004-6/2007 Clinical Fellowship, Endocrinology, Baylor College of Medicine, Houston, TX, Ashok Balasubramanyam
7/2001-6/2003 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX, Amir Halevy
6/2000-6/2001 Clinical Internship, Internal Medicine, Baylor College of Medicine, Houston, TX, Amir Halevy

Board Certifications

2016 Endocrinology, Diabetes and Metabolism
2014 Internal Medicine

Experience/Service

Academic Appointments

Chief Medical Resident, Division of Internal Medicine, Baylor College of Medicine, Houston, TX, 7/2003-6/2004

Administrative Appointments/Responsibilities

Member-Multidisciplinary Bone Health Center Steering Committee, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 7/2009-present
Member-Editorial Board for Department Newsletter/Website Committee, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2/2009-present
Member-Endocrine Center Steering Committee for the Institute of Personalized Cancer Therapy, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2008-2010
Member-Thyroid Cancer Survivorship Program, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present

Institutional Committee Activities

Member, Clinical Research Committee 3, 9/2011-8/2012
Member, Pharmacy & Therapeutics Committee, 2/2011-present
Member, Clinical Research Committee 4, 9/2010-8/2011
Member, Clinical Research Committee 2, 9/2008-8/2010
Member, Graduate Medical Education Committee, 2008-present

Honors and Awards

2012 U.S. News Top Doctors, U.S. News and World Report, Castle Connolly Medical Ltd
2011 ENDO 2011 Outstanding Abstract Award and Presidential Poster Competition Finalist, Encocrine Society 93rd Annual Meeting
2011 U.S. News Top Doctors, U.S. News and World Report, Castle Connolly Medical Ltd
2006 Travel Grant Award for Young Investigators, American Thyroid Association 77th Annual Meeting
1999 Alpha Omega Alpha Honor Society

Professional Memberships

American Association of Clinical Endocrinologists
Member, 2005-present
American College of Physicians
Member, 2000-present
American Medical Association
Member, 1996-2012
American Society for Bone and Mineral Research
Member, 2007-present
American Society of Clinical Oncology
Member, 2007-2010
American Thyroid Association
Member, 2006-present
ASBMR Women in Bone and Mineral Research Committee
Council Member, 2008-2011
Endocrine Society
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Sellin RV, Gagel RF, Sherman SI, Busaidy NL. The non-investigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. The Journal of Clinical Endocrinology & Metabolism, 11/2012. e-Pub 11/2012. PMID: 23185034.
2. Rianon N, Alex G, Callender G, Jimenez C, Hu M, Grubbs E, Moreno M, Wathoo C, Petak S, Perrier N. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. World J Surg 36(6):1320-6, 6/2012. PMID: 22278606.
3. Landry CS, Grubbs EG, Hernandez M, Hu MI, Hansen MO, Lee JE, Perrier ND. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg 147(4):338-44, 4/2012. e-Pub 12/2011. PMID: 22184134.
4. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center experience. Cancer 117(19):4381-9, 10/2011. e-Pub 3/2011. PMCID: PMC3134535.
5. Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid 21(2):189-92, 2/2011. e-Pub 12/2010. PMCID: PMC3025175.
6. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-36, 2008. PMCID: PMC2677083.

Invited Articles
1. Rich TA, Hu MI, Martin JW, Perrier ND, Waguespack SG. CDC73-related disorders. GeneReviews at GeneTests, www.genetests.org, 5/2012. PMID: 20301744.
2. Hu MI, Gagel RF. Multiple endocrine neoplasia type 2. Translational Endocrinology & Metabolism 2(4):45-76, 12/2011.
3. Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol 9(5):1-3, 5/2011. PMID: 21685868.
4. Khan MI, Waguespack SG, Hu MI. Medical management of postsurgical hypoparathyroidism. Endocr Pract 17 Suppl 1:1-19, Mar-Apr, 3/2011. e-Pub 12/2010. PMID: 21134871.
5. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218(1):47-54, 2/2011. e-Pub 9/2010. PMID: 20946574.
6. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780, 2011. e-Pub 10/2011. PMCID: PMC3189619.
7. Hu MI, Lu H, Gagel RF. Cancer Therapies and Bone Health. Curr Rheumatol Rep 12(3):177-85, 6/2010. PMID: 20437119.
8. Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3(2):75-88, 6/2009. e-Pub 5/2009. PMID: 19412668.
9. Jiménez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37(2):481-96, 2008. PMID: 18502338.
10. Hu MI, Cote G, Gagel RF. RET gene: a therapeutic target in medullary thyroid carcinoma (within issue on "Recent advances in thyroid cancer"). Current Problems in Surgery 45(3):202-212, 2008.
11. Hu MI, Gagel RF, Jimenez C. Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep 5(4):170-8, 2007. PMID: 18430392.

Editorials
1. Hu MI, Cote GJ. Medullary thyroid carcinoma: who's on first? Thyroid 22(5):451-3, 5/2012. PMID: 22545752.
Other Articles
1. Hu MI. Hypercalcemia of malignancy: current & future directions. Department of Endocrine Neoplasia and Hormonal Disorders Newsletter 5(1):1-3, 3/2012.
2. Hu MI. Multiple endocrine neoplasia type 2: a case-based discussion. Department of Endocrine Neoplasia and Hormonal Disorders Newsletters 3(2), 2010.
3. Hu MI. Building bone health in cancer patients. Department of Endocrine Neoplasia and Hormonal Disorders Newsletter 2(3), 2009.
4. Hu MI. Medical management of medullary thyroid carcinoma. Department of Endocrine Neoplasia and Hormonal Disorders Newsletter 1(2), 2008.
5. Hu MI, Hoff AO, Gagel RF. Short-term teriparatide in the treatment of postoperative hypocalcemia. EndoTrends 14(1):4-5, 2007.

Book Chapters
1. Hu MI, Jimenez C, Busaidy NL, Habra M. Long-term and late endocrine effects of cancer survivorship. In: Cancer Survivorship, 1st. In Press.
2. Waguespack SG, Grubbs EG, Hu MI. Multiple endocrine neoplasia type 2. In: Clinical Genomics: Practical Applications in Adult Patient Care. McGraw Hill. In Press.
3. Hu MI, Jimenez C, Cote GJ, Gagel RF. Medullary thyroid carcinoma. In: The Thyroid, 10th. Ed(s) Braverman L, Cooper D. Lippincott Williams & Wilkins: Philadephia, PA, 744-65, 2012.
4. Thosani S, Ahn P, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 14th. CMP Medica, http://www.cancernetwork.com/cancer-management-app via http://itunes.apple.com, e-Book 2012.
5. Alford E, Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 13th Edition. CMPMedica, 2011.
6. Hu M, Gagel RF. Multiple endocrine neoplasia type 2. In: Endocrinology, 6th edition. Ed(s) JL Jameson, LJ DeGroot. Saunders, 2010.
7. Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 12th Edition. CMPMedica, 51-70, 2010.
8. Hu MI, Sherman SI. Endocrine complications of head and neck surgery. In: Complications in Head and Neck Surgery, 2nd edition. Ed(s) Eisele, DW, 2009.
9. Hu MI, Yeung SJ, Gagel RF. Endocrine paraneoplastic syndromes. In: Internal Medicine Care of Cancer Patients. Ed(s) Escalante C, Yeung J, Gagel RF. BC Decker Inc; the Holland-Frei Series: Ontario, 2009.
10. Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont J. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach, 11th Edition. CMPMedica, 2009.
11. Hu MI, Gagel RF. Calcitonin gene family of peptides. In: Principles of Bone Biology, 3rd edition. Ed(s) Bilezikian J, Raisz L, Rodan G, 2008.

Last updated: 2/13/2013